logo
logo

Spotlight Therapeutics Raises $36.5 Million Series B To Advance A Pipeline Of Cell-Targeted In Vivo Crispr Gene Editing Biologics

Mar 22, 2022•over 3 years ago

Amount Raised

$36.5 Million

Round Type

series b

San Francisco

Description

Spotlight Therapeutics, Inc. (“Spotlight”), a biotechnology company applying new insights to develop cell-targeted in vivo CRISPR gene editing biologics, today announced a $36.5M Series B financing to fuel a drive toward the clinic.

Company Information

Company

Spotlight Therapeutics

Location

San Francisco, California, United States

About

Established in mid-2018, Spotlight Therapeutics is a privately held biotechnology company advancing a pipeline of cell-targeted in vivo CRISPR gene editing therapies. Spotlight's proprietary technology platform TAGE (Targeted Active Gene Editors) is a new class of biologics, CRISPR effectors engineered for direct delivery in vivo, to achieve cell-selective therapeutic genome editing. Spotlight's pipeline is advancing its modular programmable CRISPR effectors towards clinical studies in immuno-oncology, ophthalmic diseases and hemoglobinopathies. The company is headquartered in Hayward, California. For more information, please visit www.spotlighttx.com.

Funding Insights

Based on industry data
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech

Related People